DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice.

ABSTRACT:

Background

Previous studies have shown that the baculovirus-vectored vaccine based on the "baculovirus dual expression system (BDES)" is an effective vaccine delivery platform for malaria. However, a point of weakness remaining for use of this vaccine platform in vivo concerns viral inactivation by serum complement. In an effort to achieve complement resistance, the gene encoding the human decay-accelerating factor (hDAF) was incorporated into the BDES malaria vaccine expressing the Plasmodium falciparum circumsporozoite protein (PfCSP).

Results

The newly-developed BDES vaccine, designated BDES-sPfCSP2-Spider, effectively displayed hDAF and PfCSP on the surface of the viral envelope, resulting in complement resistance both in vitro and in vivo. Importantly, upon intramuscula

SUBMITTER: Iyori M 

PROVIDER: S-EPMC5622557 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature